Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3843 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Motor neuron disease research breakthrough

Researchers have found that the insulin-like growth factor 1 (IGF-1) dramatically increases the in vitro growth of corticospinal motor neuron (CSMN) axons – projections that carry nerve impulses

Cause for nephrotic syndrome found

Recessive mutations in a gene called phospholipase C epsilon, or PLCE1, have been identified as the cause of a kidney disease called nephrotic syndrome. Untreated nephrotic syndrome progresses

CombinatoRx arthritis drug demonstrates success

CRx-102 is an oral synergistic combination drug candidate containing the cardiovascular agent dipyridamole and a low dose of the steroid prednisolone. The trial compared CRx-102 plus a disease-modifying

Neurochem receives double recommendation

In North America, this fifth recommendation by the monitoring board was based on the recent review of the available safety data from 1,052 patients who have been on

Wyeth and Ablynx sign $212 million agreement

Ablynx is the pioneer in the discovery and development of nanobodies, a novel class of antibody-derived therapeutic proteins. The agreement will allow the companies to develop and commercialize

Raptor enters agreement to use Mesd reagents

Mesd is a chaperone protein necessary for the proper folding of the signal transduction receptors LRP5 and LRP6. Mesd-based peptides may be useful in the therapeutic regulation of

Aricept may help in radiotherapy

The drug, which is manufactured by Japan’s Eisai and co-promoted in many markets by Pfizer, will be given daily for six months to brain cancer survivors who have

Amgen drug shows activity against tumors

The assessment of AMG 706 in 120 patients showed a clinical benefit rate of 27%. Treatment-related adverse events that occurred in 15% or more of all patients were